BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29860423)

  • 1. Improvement of BDNF signalling by P42 peptide in Huntington's disease.
    Couly S; Paucard A; Bonneaud N; Maurice T; Benigno L; Jourdan C; Cohen-Solal C; Vignes M; Maschat F
    Hum Mol Genet; 2018 Sep; 27(17):3012-3028. PubMed ID: 29860423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.
    Couly S; Carles A; Denus M; Benigno-Anton L; Maschat F; Maurice T
    Neuropharmacology; 2021 Mar; 186():108467. PubMed ID: 33516737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
    Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
    J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The P42 peptide and Peptide-based therapies for Huntington's disease.
    Marelli C; Maschat F
    Orphanet J Rare Dis; 2016 Mar; 11():24. PubMed ID: 26984770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.
    Giralt A; Rodrigo T; Martín ED; Gonzalez JR; Milà M; Ceña V; Dierssen M; Canals JM; Alberch J
    Neuroscience; 2009 Feb; 158(4):1234-50. PubMed ID: 19121372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.
    Arribat Y; Talmat-Amar Y; Paucard A; Lesport P; Bonneaud N; Bauer C; Bec N; Parmentier ML; Benigno L; Larroque C; Maurel P; Maschat F
    Acta Neuropathol Commun; 2014 Aug; 2():86. PubMed ID: 25091984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
    Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
    Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity.
    Anglada-Huguet M; Vidal-Sancho L; Giralt A; García-Díaz Barriga G; Xifró X; Alberch J
    Neurobiol Dis; 2016 Nov; 95():22-34. PubMed ID: 26369879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
    Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
    J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.
    Cabezas-Llobet N; Vidal-Sancho L; Masana M; Fournier A; Alberch J; Vaudry D; Xifró X
    Mol Neurobiol; 2018 Nov; 55(11):8263-8277. PubMed ID: 29526016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
    Hathorn T; Snyder-Keller A; Messer A
    Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity.
    Pan Y; Zhu Y; Yang W; Tycksen E; Liu S; Palucki J; Zhu L; Sasaki Y; Sharma MK; Kim AH; Zhang B; Yano H
    J Biol Chem; 2018 Jul; 293(30):11850-11866. PubMed ID: 29891550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.
    Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.